Curtin School of Population Health, Curtin University, Bentley, Western Australia, Australia.
Wesfarmers Centre of Vaccines & Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia.
Birth Defects Res. 2022 Nov 15;114(19):1244-1256. doi: 10.1002/bdr2.2049. Epub 2022 Jun 9.
Seasonal inactivated influenza vaccine (IIV) is routinely recommended during pregnancy to protect both mothers and infants from complications following influenza infection. While previous studies have evaluated the risk of major structural birth defects in infants associated with prenatal administration of monovalent pandemic IIV, fewer studies have evaluated the risk associated with prenatal seasonal IIV.
We conducted a population-based cohort study of 125,866 singleton births between 2012 and 2016 in Western Australia. Birth registrations were linked to the state's registers for congenital anomalies and a state prenatal vaccination database. We estimated prevalence ratios (PR) of any major structural birth defect and defects by organ system. Vaccinated pregnancies were defined as those with a record of IIV in the first trimester. Inverse probability treatment weighting factored for baseline probability for vaccination. A Bonferroni correction was applied to account for multiple comparisons.
About 3.9% of births had a major structural birth defect. Seasonal IIV exposure during the first trimester was not associated with diagnosis of any major structural birth defect diagnosed within 1 month of birth (PR 0.98, 95% CI: 0.77, 1.28) or within 6 years of life (PR 1.02, 95% CI: 0.78, 1.35). We identified no increased risk in specific birth defects associated with seasonal IIV.
Based on registry data for up to 6 years of follow-up, results suggest there is no association between maternal influenza vaccination and risk of major structural birth defects. These results support the safety of seasonal IIV administration during pregnancy.
季节性灭活流感疫苗(IIV)通常在怀孕期间推荐使用,以保护母亲和婴儿免受流感感染后的并发症。虽然以前的研究已经评估了与产前使用单价大流行性 IIV 相关的婴儿主要结构出生缺陷的风险,但较少的研究评估了与产前季节性 IIV 相关的风险。
我们对 2012 年至 2016 年期间西澳大利亚 125866 例单胎出生进行了基于人群的队列研究。出生登记与该州先天性异常登记册和州产前疫苗接种数据库相关联。我们估计了任何主要结构出生缺陷和器官系统缺陷的患病率比(PR)。接种疫苗的妊娠定义为在妊娠早期有 IIV 记录的妊娠。逆概率治疗权重考虑了接种疫苗的基线概率。应用 Bonferroni 校正法考虑多重比较。
约 3.9%的出生存在主要结构出生缺陷。妊娠早期接种季节性 IIV 与出生后 1 个月内(PR 0.98,95%CI:0.77,1.28)或 6 年内(PR 1.02,95%CI:0.78,1.35)诊断的任何主要结构出生缺陷无关。我们没有发现与季节性 IIV 相关的特定出生缺陷风险增加。
基于长达 6 年的随访登记数据,结果表明母亲流感疫苗接种与主要结构出生缺陷的风险之间没有关联。这些结果支持在怀孕期间使用季节性 IIV 的安全性。